DDInter1141 DDInter1925
17-Hydroxy-6-methylpregna-3,6-diene-3,20-dione. A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer.
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
Megestrol acetate {u} (Compound) resembles {v} (Compound) Progesterone
Progesterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vemurafenib
Megestrol acetate {u} (Compound) resembles {v} (Compound) Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vemurafenib
Megestrol acetate {u} (Compound) resembles {v} (Compound) Progesterone
Progesterone {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Vemurafenib
Megestrol acetate {u} (Compound) resembles {v} (Compound) Dydrogesterone
Dydrogesterone {u} (Compound) resembles {v} (Compound) Exemestane
Exemestane {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vemurafenib
Megestrol acetate {u} (Compound) resembles {v} (Compound) Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Vemurafenib
Megestrol acetate {u} (Compound) resembles {v} (Compound) Dydrogesterone
Dydrogesterone {u} (Compound) resembles {v} (Compound) Progesterone
Progesterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vemurafenib
Megestrol acetate {u} (Compound) resembles {v} (Compound) Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} (Compound) downregulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Megestrol acetate {u} (Compound) resembles {v} (Compound) Difluprednate
Difluprednate {u} (Compound) causes {v} (Side Effect) Uveitis
Uveitis {u} (Side Effect) is caused by {v} (Compound) Vemurafenib
Megestrol acetate {u} (Compound) resembles {v} (Compound) Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} (Compound) upregulates {v} (Gene) SPAG4
SPAG4 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Megestrol acetate {u} (Compound) resembles {v} (Compound) Progesterone
Progesterone {u} (Compound) upregulates {v} (Gene) GPATCH8
GPATCH8 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Megestrol acetate (Compound) resembles Progesterone (Compound) and Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Megestrol acetate (Compound) resembles Medroxyprogesterone acetate (Compound) and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Megestrol acetate (Compound) resembles Progesterone (Compound) and Progesterone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Megestrol acetate (Compound) resembles Dydrogesterone (Compound) and Dydrogesterone (Compound) resembles Exemestane (Compound) and Exemestane may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Megestrol acetate (Compound) resembles Medroxyprogesterone acetate (Compound) and Medroxyprogesterone acetate (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Megestrol acetate (Compound) resembles Dydrogesterone (Compound) and Dydrogesterone (Compound) resembles Progesterone (Compound) and Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Megestrol acetate (Compound) resembles Medroxyprogesterone acetate (Compound) and Medroxyprogesterone acetate (Compound) downregulates MTHFD2 (Gene) and MTHFD2 (Gene) is upregulated by Vemurafenib (Compound)
Megestrol acetate (Compound) resembles Difluprednate (Compound) and Difluprednate (Compound) causes Uveitis (Side Effect) and Uveitis (Side Effect) is caused by Vemurafenib (Compound)
Megestrol acetate (Compound) resembles Medroxyprogesterone acetate (Compound) and Medroxyprogesterone acetate (Compound) upregulates SPAG4 (Gene) and SPAG4 (Gene) is upregulated by Vemurafenib (Compound)
Megestrol acetate (Compound) resembles Progesterone (Compound) and Progesterone (Compound) upregulates GPATCH8 (Gene) and GPATCH8 (Gene) is upregulated by Vemurafenib (Compound)